Zydelig for Chronic Lymphocytic Leukemia – Details


( Last Updated : September 2, 2015)
Generic Name:
Idelalisib
Project Status:
Complete
Therapeutic Area:
Chronic lymphocytic leukemia
Manufacturer:
Gilead Sciences, Inc.
Brand Name:
Zydelig
Project Line:
Reimbursement Review
Project Number:
PC0057-000
NOC Date:

Details


Strength:
100mg and 150mg tablets
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)
Review Status:
Complete
Sponsor:
Gilead Sciences, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.